Navigation Links
Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification

ion label for Flurizan."

About Flurizan(TM)

Myriad has two Phase 3 trials of Flurizan ongoing in patients with mild Alzheimer's disease. In each study, participants are taking 800 mg of Flurizan or placebo twice daily, and participants enrolled will have taken the study drug for 18 months. Flurizan is the first in a new class of drug candidates known as Selective Amyloid beta-42 Lowering Agents (SALAs). Flurizan lowered levels of Abeta42 in cellular assays and animal models. Abeta42 is the primary constituent of senile plaque that accumulates in the brain of patients with Alzheimer's disease. It is thought to be the key initiator of Alzheimer's disease, since Abeta42 has the greatest tendency to aggregate, cause neuronal damage and initiate amyloid deposits in the brain. Most genetic mutations that cause early-onset Alzheimer's disease appear to do so by increasing production of Abeta42. Myriad believes that Flurizan is the most advanced drug candidate that modifies the production of Abeta42 to be evaluated in a clinical trial for the treatment of Alzheimer's disease.

About Myriad

Myriad Genetics, Inc. is a biopharmaceutical company focused on the development and marketing of novel healthcare products. The Company develops and markets molecular diagnostic products, and is developing and intends to market therapeutic products. Myriad's news and other information are available on the Company's Web site at www.myriad.com. Flurizan is a trademark of Myriad Genetics, Inc. in the United States and other countries.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include whether the Flurizan Phase 3 study design may demonstrate disease modification; the Company's use of the Natural History Staggered Start trial design and trial analysis methodology in its Flurizan Phase
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Myriad Genetics Presents Tumor Origin Technology at AACR
2. Myriad Genetics Presents Azixas Mode of Action at AACR
3. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
4. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
5. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
8. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
9. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
Post Your Comments:
(Date:11/26/2014)... 26, 2014  Aridis Pharmaceuticals, Inc., a biopharmaceutical ... for infectious diseases, announced today the addition of ... key opinion leader in the areas of pneumonia ... Founder and Chief Executive Officer, ... Opal,s extensive experience investigating bacterial toxins and key ...
(Date:11/26/2014)... WASHINGTON and NEW YORK ... 2014 As the leading distributor of market ... a new research report by IQ4I Research and Consultancy ... To learn more about IQ4I Research visit: ... Active Pharmaceutical Ingredients Global Market – Forecast ...
(Date:11/26/2014)... Nov. 25, 2014  At the American Dental Association,s ... this October, KaVo Kerr Group was honored to be ... attendees the opportunity to see and test the Best ... leaders deliver lectures on the latest developments in dental ... the new DEXIS CariVu Caries Detection Device and Kerr ...
Breaking Medicine Technology:Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3
... SUNNYVALE, Calif., Nov. 10, 2011 Accuray Incorporated (Nasdaq: ... that its president and chief executive officer, Euan S. Thomson, ... 8th Annual Healthcare Conference in New York City on Tuesday ... Thomson is also scheduled to present at the Stephens Fall ...
... healthcare distributors continue to provide increased value to the ... challenges in the pharmaceutical industry, according to The ... released by the Center for Healthcare Supply Chain Research. ... Healthcare Distribution Management Association (HDMA).   ...
Cached Medicine Technology:Pharmaceutical Distributors Continue to Deliver Operational Efficiencies and Value to U.S. Healthcare System Amidst Economic and Regulatory Challenges 2Pharmaceutical Distributors Continue to Deliver Operational Efficiencies and Value to U.S. Healthcare System Amidst Economic and Regulatory Challenges 3Pharmaceutical Distributors Continue to Deliver Operational Efficiencies and Value to U.S. Healthcare System Amidst Economic and Regulatory Challenges 4
(Date:11/28/2014)... November 28, 2014 Dr. Paul Vitenas, one of ... a Glitter & Glow Holiday Event for those in the area ... at his practice. Glitter & Glow will take place on December ... new location in the heart of Houston at 4208 Richmond Ave. ... and hope that you will come and celebrate the season with ...
(Date:11/28/2014)... 2014 Written and narrated by award winning ... releases the “The Happiest Man In the World: Life ... of how and why Project C.U.R.E. came to be. , ... Josie and the Reverend Richard W. Jackson, Dr. Jackson exceeded ... 30, but realized that he wasn’t happy. Prompted by this ...
(Date:11/28/2014)... Alex Kramer HealthDay Reporter , ... in the kitchen, through cooking classes or at home, may ... a recent review. Cooking programs and classes for children ... to the new research. And, although the review didn,t look ... such programs might help children develop long-lasting healthy habits. ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 An inventor and ... light on a patient’s filling and it was almost impossible ... ergonomic curing light," she said. , The patent-pending Access Light ... eases access to areas of the mouth, as well as ... efficiency and safety. Easy to use and clean, it also ...
(Date:11/28/2014)... New York, New York (PRWEB) November 28, 2014 ... lawsuits ( http://www.consumerinjurylawyers.com/stryker-rejuvenate/stryker-hip-lawsuits/ ) have now been filed ... pair of recalled metal implants, Bernstein Liebhard LLP ... November 18th in Bergen County Superior Court reflects ... and ABG II modular-neck hip stems, which were ...
Breaking Medicine News(10 mins):Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3Health News:Thanksgiving Weekend Audiobook Treat! “The Happiest Man In the World: Life Lessons From a Cultural Economist” by Dr. James W. Jackson 2Health News:Want Kids to Eat Better? Get Them Cooking 2Health News:Want Kids to Eat Better? Get Them Cooking 3Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 2Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 3
... of OTC drugs grew by 2.4% from $17.8 million ... the latest research in Nonprescription Drugs USA 2008: ... research firm Kline & Company.Private-label OTC medicines were up ... and allergy medicines posted the highest growth last year, ...
... sensitive gradiometer instrument has been switched on and is ... is specifically designed to measure Earth,s gravity field with ... we have seen from the gradiometer from the moment ... working in very good health and provide meaningful data," ...
... Gentiva Health Services, Inc. (Nasdaq: GTIV ), ... that it has scheduled a conference call and web cast ... discuss operating results for the first quarter ended March 29, ... morning of April 30 before pre-market trading. The conference call ...
... Super Bowl MVP Eli Manning , who serves ... business and corporate leaders on Monday, April 6, for a private ... and a member of the March of Dimes NY Division Board ... 3 Times Square, in New York. CBS 2 News Co-Anchor, Maurice ...
... ATLANTA, April 8 Amoena, the worldwide ... the introduction of The Hannah Collection, the ... E and Aloe to ease discomfort after ... )(Photo: http://www.newscom.com/cgi-bin/prnh/20090408/CL96087 ...
... MYL ) today announced the settlement of all ... generic version of Schering- Plough,s Clarinex(R) allergy medication. This ... of New Jersey since September 2006.Pursuant to the settlement, ... 5 mg, in the U.S. on July 1, 2012, ...
Cached Medicine News:Health News:Private-label OTC Drugs Post Solid Gains in 2008, According to Kline 2Health News:Private-label OTC Drugs Post Solid Gains in 2008, According to Kline 3Health News:GOCE's 'heart' starts beating 2Health News:Gentiva(R) Health Services Schedules First Quarter Earnings Call and Web Cast for Thursday, April 30, 2009 2Health News:Gentiva(R) Health Services Schedules First Quarter Earnings Call and Web Cast for Thursday, April 30, 2009 3Health News:Eli Manning and Top Corporate Leaders Rally to Help Save Babies 2Health News:Amoena Introduces First Post Surgical Garments With Vitamin E & Aloe to Help Soothe and Comfort After Breast Surgery 2Health News:Mylan Announces Clarinex(R) Settlement Agreement 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: